Results of Visfatin on podocyte injury. Credit: 2023 Koka et al.
A wonderful research paper titled,” Contribution of membrane raft redox signaling to visfatin-induced inflammasome activation and podocyte injury,” was recently published in Aging. It’s a fascinating read – be sure to check it out here!
The number of obese patients with end-stage kidney disease has significantly increased worldwide in recent years. Researchers from the University of Houston, Texas A&M University and the University of California Riverside have made progress on understanding how obesity contributes to the development of chronic kidney disease. It’s all about visfatin-induced NLRP3 inflammasome activation.
The molecular mechanisms behind visfatin-induced NLRP3 inflammasome activation and podocyte injury are still unknown. The latest study addressed these unknowns, examining whether the membrane raft (MR) redox signaling path plays a role in the activation and formation of inflammasomes in podocytes.
Credit: Impact Journals LLC
The authors explained, “In this research study, it is proposed that visfatin causes the NLRP3 inflammasome activation in podocytes, causing glomerular inflammatory injury in the kidney and the advancement of CKD, might be mainly driven by NADPH oxidase-mediated membrane raft redox signaling.”
They discovered that visfatin stimulation led to an aggregation of NADPH oxidase subunits and the development of an MR redox signaling platform in podocytes. The findings suggest that visfatin promotes membrane raft clustering in the membrane of podocytes to form redox signaling platforms by aggregation and activation of NADPH oxidase subunits, resulting in NLRP3 inflammasome activation and podocyte injury.
Furthermore, prior treatments with DPI, WEHD, and MCD reduced the visfatin-induced podocin and nephrin decrease, which are markers of podocyte damage. These findings have implications for the treatment and understanding of chronic kidney disease, a serious public health issue affecting millions of patients worldwide.
If you want to dive deeper into the findings, learn more about membrane raft redox signaling and chronic kidney disease, the full research paper is available to read here!
